ARTV
Artiva Biotherapeutics, Inc.
$8.54
+6.75%
$211.1M
No data for this timeframe.
Vol
Market Cap$211.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders20 funds
Inst. Value$73.9M
Inst. Activity0 buys / 3 sells
Insider Activity6B / 5S
Insider Net $$119.7M
SEC Reports8
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001817241·Prev Close $8.00
Recent Activity
Jun 11, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 548,580 shares
Director @ $7.91 ($4.3M)
Jun 10, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 103 shares
Director @ $7.00 ($721.00)
Jun 9, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 479,039 shares
Director @ $6.91 ($3.3M)
Jun 8, 2026
Press
Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 respons
Impact 7/10
Jun 8, 2026
fda
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refr
May 20, 2026
SEC
CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026, just 11 days after
CLUSTER — Impact 5/10
May 19, 2026
SEC
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22,
8-K — Impact 3/10
May 18, 2026
SEC
Artiva Biotherapeutics (ARTV) director Christopher Horan filed a Form 144 to sell 7,500 shares (~$69K estimated value) a
144 — Impact 2/10
Price Targets
$35.80
+319.2% upside
Strong Buy
Current $8.54
Low $23.00
Median $40.00
High $41.00
5 analysts
$23.00
$41.00
Analyst Ratings
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Needham | REITERATE | Buy → Buy |
| May 12, 2026 | Needham | MAINTAIN | Buy → Buy |
| May 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.64 | $-0.80 — $-0.43 | 26% YoY | 4 |
| Next Q | $-0.52 | $-0.56 — $-0.50 | 41% YoY | 4 |
| Current FY | $-2.43 | $-2.67 — $-2.18 | 29% YoY | 4 |
| Next FY | $-2.81 | $-3.50 — $-2.47 | -16% YoY | 4 |
Latest Reports
BULLISH
Press
7/10
Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 respons
Jun 8, 2026
BEARISH
CLUSTER
5/10
CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026, just 11 days after
May 20, 2026
NEUTRAL
8-K
3/10
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22,
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $63.5M | NEW |
| FRANKLIN RESOURCES INC | $3.4M | — |
| BlackRock, Inc. | $1.4M | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | — |
| WELLINGTON MANAGEMENT GROUP LLP | $1.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | RA CAPITAL | BUY | $4.3M |
| Jun 10, 2026 | RA CAPITAL | BUY | $721.00 |
| Jun 9, 2026 | RA CAPITAL | BUY | $3.3M |
| May 19, 2026 | Horan Christopher | SELL | $63.1K |
| May 19, 2026 | Aslan Fred | SELL | $244.3K |
20 institutional holders with $73.9M total value (11,469,416 shares) as of 2026-Q1. Top holders: RA, FRANKLIN, BlackRock,. Net selling activity: 3 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9,853,302 | $63.5M | 85.9% | NEW |
| 2 | FRANKLIN RESOURCES INC | 520,327 | $3.4M | 4.5% | — |
| 3 | BlackRock, Inc. | 213,388 | $1.4M | 1.9% | TRIM -27.8% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 207,686 | $1.3M | 1.8% | — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 194,108 | $1.3M | 1.7% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 115,041 | $740.9K | 1.0% | DOUBLED +611.4% |
| 7 | Alyeska Investment Group, L.P. | 100,000 | $644.0K | 0.9% | — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 80,038 | $515.4K | 0.7% | TRIM -31.1% |
| 9 | STATE STREET CORP | 35,824 | $230.7K | 0.3% | TRIM -40.1% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 32,810 | $211.3K | 0.3% | — |
| 11 | PANAGORA ASSET MANAGEMENT INC | 30,702 | $197.7K | 0.3% | — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 20,370 | $131.2K | 0.2% | — |
| 13 | MORGAN STANLEY | 16,377 | $105.5K | 0.1% | TRIM -39.5% |
| 14 | CITADEL ADVISORS LLC | 15,870 | $102.2K | 0.1% | DOUBLED +419.3% |
| 15 | GOLDMAN SACHS GROUP INC | 11,465 | $73.8K | 0.1% | — |
| 16 | OMERS ADMINISTRATION Corp | 11,400 | $73.4K | 0.1% | TRIM -46.0% |
| 17 | Russell Investments Group, Ltd. | 5,491 | $35.4K | 0.0% | — |
| 18 | FMR LLC | 3,529 | $22.7K | 0.0% | TRIM -27.7% |
| 19 | WELLS FARGO & COMPANY/MN | 1,500 | $9.7K | 0.0% | NEAR_EXIT -83.7% |
| 20 | ROYAL BANK OF CANADA | 188 | $1.0K | 0.0% | DOUBLED +134.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 116,200 | 80,038 | -31.1% | $515.4K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 27,072 | 16,377 | -39.5% | $105.5K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 21,100 | 11,400 | -46.0% | $73.4K | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 159,118 | 246,006 | +54.6% | $1.1M | 2025-Q4 |
| BlackRock, Inc. | TRIM | 294,422 | 212,538 | -27.8% | $911.8K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 20,364 | 144,864 | +611.4% | $621.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 79,147 | 116,200 | +46.8% | $498.5K | 2025-Q4 |
| STATE STREET CORP | TRIM | 59,824 | 35,824 | -40.1% | $153.7K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 42,829 | 27,072 | -36.8% | $116.1K | 2025-Q4 |
| FMR LLC | TRIM | 4,920 | 3,558 | -27.7% | $15.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 16,145 | 113 | -99.3% | $484.00 | 2025-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 153,739 | 798,397 | +419.3% | $2.3M | 2025-Q3 |
| BlackRock, Inc. | TRIM | 485,727 | 294,422 | -39.4% | $845.0K | 2025-Q3 |
| VANGUARD GROUP INC | TRIM | 232,972 | 159,118 | -31.7% | $456.7K | 2025-Q3 |
| UBS Group AG | DOUBLED | 3,337 | 21,143 | +533.6% | $60.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,955 | 16,145 | +225.8% | $46.3K | 2025-Q3 |
| BARCLAYS PLC | DOUBLED | 1,906 | 12,696 | +566.1% | $36.4K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 42,277 | 4,920 | -88.4% | $14.1K | 2025-Q3 |
| HRT FINANCIAL LP | TRIM | 77,656 | 26,953 | -65.3% | $77.00 | 2025-Q3 |
| CWM, LLC | NEAR_EXIT | 185 | 10 | -94.6% | — | 2025-Q2 |
| VANGUARD GROUP INC | TRIM | 858,214 | 232,972 | -72.9% | $351.8K | 2025-Q2 |
| STATE STREET CORP | TRIM | 171,783 | 62,874 | -63.4% | $94.9K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 43,077 | 3,337 | -92.3% | $5.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 12,659 | 2,064 | -83.7% | $3.1K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 478 | 1,120 | +134.3% | $2.0K | 2025-Q2 |
9 unique insiders with 14 transactions. Net insider value: $119.7M ($120.1M bought, $477.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 548,580 | $7.91 | $4.3M |
| Jun 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 103 | $7.00 | $721.00 |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 479,039 | $6.91 | $3.3M |
| May 19, 2026 | Horan Christopher | Chief Tech Operations Officer | SELL | 7,002 | $9.01 | $63.1K |
| May 19, 2026 | Aslan Fred | Chief Executive Officer | SELL | 27,116 | $9.01 | $244.3K |
| May 19, 2026 | Banerjee Subhashis | Chief Medical Officer | SELL | 7,037 | $9.01 | $63.4K |
| May 19, 2026 | Bush Jennifer | COO, CLO, Compliance Officer | SELL | 8,790 | $9.01 | $79.2K |
| May 19, 2026 | Raymon Heather | SVP, Research and Development | SELL | 3,095 | $9.01 | $27.9K |
| May 18, 2026 | Miralles Gines Diego | President & Head of R&D | AWARD | 77,500 | — | — |
| May 18, 2026 | Miralles Gines Diego | President & Head of R&D | AWARD | 232,500 | — | — |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 6,510,416 | $11.52 | $75.0M |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 2,170,138 | $11.52 | $25.0M |
| May 11, 2026 | GC Corp. | 10%+ Owner | BUY | 1,085,069 | $11.52 | $12.5M |
| Mar 10, 2026 | Huston Thad Allen | Chief Financial Officer | AWARD | 220,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 4.6/10.
BEARISH
CLUSTER
5/10
CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026
May 20, 2026
NEUTRAL
8-K
3/10
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departin
May 19, 2026
NEUTRAL
144
2/10
Artiva Biotherapeutics (ARTV) director Christopher Horan filed a Form 144 to sell 7,500 shares (~$69
May 18, 2026
NEUTRAL
144
2/10
Jennifer Bush, an officer and director of Artiva Biotherapeutics, filed a Form 144 to sell 9,000 sha
May 18, 2026
BEARISH
8-K
7/10
Artiva Biotherapeutics priced a $300M underwritten public offering of 23.9M shares and pre-funded wa
May 8, 2026
BULLISH
8-K
8/10
Artiva reported Q1 2026 net loss of $23.5M ($0.95/share), slightly wider than the $20.3M loss a year
May 8, 2026
BULLISH
PRESS-RELEASE
7/10
Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while r
May 8, 2026
NEUTRAL
8-K, 8-K
3/10
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026.
Feb 24, 2026
BULLISH
7/10
Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including
Jun 8, 2026
BULLISH
8/10
Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026)
May 19, 2026
NEUTRAL
4/10
Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles br
May 19, 2026
BULLISH
7/10
Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing
May 8, 2026
NEUTRAL
4/10
Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83
Mar 10, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$35.80 mean target
+319.2% upside
Strong Buy (1.17)
$23.00 Low
$41.00 High
| Metric | Value |
|---|---|
| Current Price | $8.54 |
| Target Low | $23.00 |
| Target Mean | $35.80 |
| Target Median | $40.00 |
| Target High | $41.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.64 | $-0.80 | $-0.43 | 26.2% | — | — | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.52 | $-0.56 | $-0.50 | 40.6% | — | — | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-2.43 | $-2.67 | $-2.18 | 29.1% | — | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-2.81 | $-3.50 | $-2.47 | -15.7% | — | 1↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.642 | |
| 7d ago | $-0.642 | |
| 30d ago | $0.000 | -0.642 |
| 60d ago | $-0.770 | +0.128 |
| 90d ago | $0.000 | -0.642 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Needham | REITERATE | Buy | Buy |
| May 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 4, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 11, 2026 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
fda
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
May 28, 2026
other
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 19, 2026
fda
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
<p>SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=FlxOgSzY8aVFzr06fu2NYsbh8Rh_MtDAMkwmeUnD04myJan-s
May 19, 2026
leadership
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 8, 2026
other
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
earnings
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 8, 2026
fda
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational
May 7, 2026
earnings_calendar
ARTV Q1 2026 Earnings Scheduled — 2026-05-07
Apr 8, 2026
other
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Apr 3, 2026
Clinical Trial
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase Phase 2 — COMPLETED
Mar 30, 2026
earnings_calendar
ARTV Q4 2025 Earnings Scheduled — 2026-03-30
Mar 10, 2026
earnings
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
<p align="center"><em>Initial clinical response data for AlloNK<sup>®</sup> in refractory rheumatoid arthritis (RA) expected in first half of 2026</em